#### (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 21 December 2000 (21.12.2000)

(10) International Publication Number

(51) International Patent Classification7: 14/47, C12N 15/10, A61P 35/00

WO 00/77031 A3 C07K 7/08. (81) Designated States (national): AE, AL, AM, AT, AU, AZ,

(21) International Application Number: PCT/CA00/00711

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language: English

(26) Publication Language:

English

(30) Priority Data: 60/139,263 15 June 1999 (15.06.1999) US

- (71) Applicant (for all designated States except US): UNIVER-SITY HEALTH NETWORK [CA/CA]; Room 7-504, 610 University Avenue, Toronto, Ontario M5G 2M9 (CA),
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GARIEPY, Jean [CA/CA]; 29 Elmsthorpe Avenue, Toronto, Ontario M5P 2L5 (CA), YANG, Shaoxian [CA/CA]; 309-36 Thorncliffe Park Drive, Toronto, Ontario M4H 1J8 (CA).
- (74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).

BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL. IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published.

With international search report.

(88) Date of publication of the international search report: 19 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUC1 LIGANDS

(57) Abstract: Novel ligands that bind to MUC1 are disclosed. The ligands were isolated using an improved phage display technique using MUC1 tandern repeat as a target. Uses of the ligand to detect, monitor or treat cancer as well as to prepare antibodies is also described.

International Application No PCT/CA 00/00711

Relevant to claim No.

1-33

A. CLASSIF	CO7K7/08	TMATTER		
IPC 7	C07K7/98	C07K14/47	C12N15/10	A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

P.X

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Minimum documentation searched (classification system followed by classification symbols)  $\frac{1}{1}$  PC  $\frac{1}{7}$  CO7K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, CHEM ABS Data, MEDLINE

Citation of document, with Indication, where appropriate, of the relevant passages

short peptide ligands that bind specifically to the breast tumor-associated MUCI epitope." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL.

GARIEPY JEAN ET AL: "Identification of

FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03) 101-102, XP600949494 91st Annual Meeting of the A Association for Cancer Resea Francisco, California, USA; 2000, March, 2000 ISSN: 0197-016X abstract	merican rch.;San		
	-/		
	X Potent turnity members are listed in annex.		
	A Tracking members are used at almos.		
Special categories of cited documents:  'A' document defining the general state of the art which is not considered to be of particular relevance.	"T" later document published after the International filing date or priority date and not in conflict with the application but clied to understand the principle or theory underlying the invention.		
"E" earlier document but published on or efter the International filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another	involve an inventive step when the document is taken alone		
citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means:	"Of document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu- ments, such combination being obvious to e person skilled		
"P" document published prior to the international filling date but later than the priority date claimed	in the art. "A" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search recort		
28 September 2000	D5 D1 2001		
Name and mailing address of the ISA	Authorized officer -		

European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 349-2040, Tx. 31 651 epo nl, Fax: (+31-70) 349-3016

Cervigni, S

PCT/CA 00/00711

	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 96 09411 A (CYTOGEN CORP) 28 March 1996 (1996-03-28)	1-3,8, 15-33
	Seq Id No 64 abstract; claims; example 6.2; table 7	
х	MANOUTCHARIAN KAREN ET AL: "Characterization of cerebrospinal fluid antibody specificities in neurocysticercosis using phage display peptide library." CLINICAL IMMUNOLOGY (ORLANDO), vol. 91, no. 1, April 1999 (1999-04), pages 117-121, XP000946486 ISSN: 1521-6616 Phage Al2 abstract: table 2	1-3,8-10
A	abstract, table 2	20-26
X	WO 92 18534 A (ANTISOME LTD) 29 October 1992 (1992-10-29)	1-3, 16-19, 28-33
	abstract; claims page 7, paragraph 1; example 3; table 6	
A	LAING P ET AL: "SELECTION OF PEPTIDE LIGAMOS FOR THE ANTIMUCIN CORE ANTIBODY C595 USING PHAGE 015YLAY TECHNOLOGY: DEFINITION OF CANDIDATE EPITOPES FOR A CANCER VACCINE AND ATTEMPORATE OF CLINICAL PATHOLOGY, GB, LONDON, VOI. 48 no. 3, 1995, pages M136-M141, XP800906851 15SM: 0821-9746	
A	MO 97 11715 A (AUSTIN RESEARCH INST ;SANDRIN MAURO SERGIO (AU); MCKENZIE IAN _FARQ) 3 April 1997 (1997-04-03)	
A	APOSTOLOPOULOS V ET AL: "CELLULAR MUCINS: TARGETS FOR INMUNOTHERAPY" CRITICAL REVIEWS IN INMUNOLOGY,XX,CRC PRESS, INC. vol. 14, no. 3/94, 1994, pages 293-309, XP002071247 ISSN: 1040-8401	
4	**	

International application No. PCT/CA 00/00711

B x I Observations where certain claims were found unsearchabl (Continuation 1 item 1 of first sheet)
This International Search Report has not been established in respect of contain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 29 is directed at least in part to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Representation in the property of the property of the property of the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:    See FURTHER INFORMATION sheet PCT/TSA/210
Claims Nos.:     because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all regulred additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required addisonal search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
·
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
see further information sheet, invention 1
Remark on Protest The additional search (ses were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8

Claim 8 relates to an extremely large number of possible compounds. Support within the meaning of Article 5 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Moreover, a preliminary search for peptides containing the sequence Pro-Aaa-Pro has given more than 150.000 compounds disclosed in the prior art. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely to the compounds disclosed in claims 9-10 and extended to those containing the

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following

receipt of the search report or during any Chapter II procedure.

sequence Pro-Aaa-Pro prepared in the examples and/or listed in claim 15.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8-10, 20-26 (all complete); 1-3, 15-19, 27-33 (all partially)

Isolated and purified ligands that bind to MUC1 comprising the sequence Pro-Aaa-Pro, method for their isolation, uses in therapy and diagnostics and antibodies binding them.

2. Claims: 4-7, 11-14 (all complete); 1-3, 15-19, 27-33 (all partially)

Isolated and purified ligands disclosed in claim 1, as far as not covered by subject 1, their uses in therapy and diagnostics and antibodies binding them.

information on patent family members

PCT/CA 00/00711

		111/11	,,
	Publication date	Patent femily member(s)	Publication date
A	28-03-1996	US 5885577 A AU 3719395 A CA 2200684 A CZ 9700855 A EP 0789783 A JP 10506463 T US 6015561 A ZA 9507989 A	23-03-1999 09-04-1996 28-03-1996 14-01-1998 20-08-1997 23-06-1998 18-01-2000 18-04-1996
A	29-10-1992	AT 159727 T DE 69222956 D DE 69222956 D OK 672663 T EP 0672663 A ES 2111066 T GB 2270078 A; GR 3025982 T JP 6506927 T US 5591593 A US 6107469 A US 5833943 A	15-11-1997 04-12-1997 09-04-1998 18-05-1998 20-09-1995 01-03-1998 02-03-1994 30-04-1998 04-08-1994 07-01-1997 22-08-2000 10-11-1998
A	03-04-1997	AU 7079396 A AU 707223 B AU 7079496 A WO 9711963 A CA 2233447 A EP 00859627 A JP 2000506493 T	17-04-1997 08-07-1999 17-04-1997 03-04-1997 26-08-1998 30-05-2000
	A	A 28-03-1996  A 29-10-1992	A 28-03-1996 US 5885577 A AU 3719395 A CA 2200684 A CZ 9700855 A EP 0789783 A JP 10506463 T US 6015561 A ZA 9507989 A A 29-10-1992 AT 159727 T DE 69222956 D DE 69222956 D DE 69222956 T DK 672063 T EP 0672063 A ES 2111066 T GB 2270078 A,B GR 3025982 T JP 6506927 T US 5591593 A US 6107469 A US 5833943 A A 03-04-1997 AU 7079396 A AU 70792496 A WO 9711963 A CA 2233447 A EP 0859627 T